Navigation Links
Roche NimbleGen and Caliper Collaborate to Offer Automated Target Enrichment Pipeline Solution for Next-Generation Sequencing
Date:7/12/2011

MADISON, Wis. and HOPKINTON, Mass., July 12, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Caliper Life Sciences, Inc. (NASDAQ: CALP) today announced a co-marketing agreement for the development and optimization of automated protocols for the NimbleGen SeqCap EZ Library solution-based capture method for Caliper's Sciclone® NGS Workstation.  The collaboration aims to simplify high throughput targeted resequencing workflows by developing automated methods for sequencing library preparation and enrichment of target regions, quantification, and quality control. The automated methods will enable biomedical researchers worldwide to analyze large cohorts to discover and confirm genetic variants that contribute to human disease.

"Roche NimbleGen is committed to providing the research community with innovative and enabling solutions for targeted resequencing," said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.  "The continued exponential growth of sequencing throughput and the volume of samples to be analyzed has shifted the bottleneck to sample preparation and process control. By combining our solutions with Caliper's NGS workstation, the bottlenecks are eliminated, creating the capacity to analyze large cohorts and optimize research efforts."

"Caliper's Sciclone NGS Workstation significantly accelerates high throughput sequencing sample preparation and enrichment for numerous sequencing chemistries and workflows," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "Together Caliper and Roche NimbleGen are developing targeted sequencing applications that enable studies that analyze variants across large populations to detect and better understand the causal agents of disease."

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.  

For more information about Roche NimbleGen, please visit www.nimblegen.com.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions.

Caliper has developed a complete suite of next generation sequencing tools including the Sciclone NGS Workstation for sequencing sample preparation, the LabChip® GX for library quantification and quality control, and the preparative LabChip XT that automates the gel isolation steps for library purification. For more information please visit www.caliperls.com.

For additional information about Caliper's solutions for next generation sequencing, please visit www.caliperls.com/genomics.

NimbleGen and SeqCap are trademarks of Roche.  Caliper, Sciclone, and LabChip are registered trademarks of Caliper Life Sciences, Inc.  Other brands or product names are trademarks of their respective holders.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In Support of the International Day of the African Child, Roche Hosts Annual Childrens Walk
2. Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date
3. Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
4. Florida Hospital First U.S. Site to Adopt New Automated Laboratory Solution From Roche
5. Roche Symposium Showcases Accomplishments of Next Generation of Chemists
6. Roche Submits Application for Clearance of Chlamydia and Gonorrhoeae Test
7. Rochester Medical Reports Second Quarter Results
8. Rochester Medical Announces Second Quarter 2011 Earnings Conference Call Thursday, May 5, 2011
9. Roche Launches EMR Interface for VA to Facilitate Diabetes Management
10. Rochester Medical Completes Acquisition of Laprolan
11. MITs Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... 19, 2017 Companion ... response in pets such as canine, avian and ... various types such as Attenuated Live Vaccines, Conjugate ... Vaccines and Recombinant Vaccines. Attenuated live vaccines are ... bacteria, which have been weakend under laboratory conditions. ...
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
Breaking Medicine Technology:
(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... California (PRWEB) , ... April 28, 2017 , ... ... T8 Direct Replace tubes . These lamps offer an instant energy-saving solution for ... need to rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
Breaking Medicine News(10 mins):